Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience

被引:6
|
作者
Figueroa, R. [1 ]
Alfonso, A. [1 ]
Lopez-Picazo, J. [2 ]
Gil-Bazo, I. [2 ]
Garcia-Mouriz, A. [3 ]
Hermida, J. [4 ,5 ]
Paramo, J. A. [1 ,5 ]
Lecumberri, R. [1 ,5 ]
机构
[1] Univ Clin Navarra, Hematol Serv, Ave Pio XII 36, Pamplona 31008, Spain
[2] Univ Clin Navarra, Dept Oncol, Pamplona, Spain
[3] Univ Clin Navarra, Informat Serv, Pamplona, Spain
[4] Univ Navarra, Ctr Appl Med Res, Pamplona, Spain
[5] Inst Salud Carlos III, Ctr Invest Biomed Red CIBER CV, Madrid, Spain
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2019年 / 21卷 / 06期
关键词
Cancer; Electronic alerts; Low molecular weight heparin; Prophylaxis; Venous thromboembolism; PREVENT VENOUS THROMBOEMBOLISM; CLINICAL-PRACTICE; ELECTRONIC ALERTS; THROMBOPROPHYLAXIS; RISK;
D O I
10.1007/s12094-018-1986-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThromboprophylaxis use among medical inpatients, including cancer patients, is suboptimal. We aimed to evaluate the impact of a novel multiscreen version (v2.0) of an e-alert system for VTE prevention in hospitalised cancer medical patients compared to the original software.MethodsProspective study including 989 consecutive adult cancer patients with high-risk of VTE. Patients were followed-up 30days post-discharge. Two periods were defined, according to the operative software.ResultsE-alert v2.0 was associated with an increase in the use of LMWH prophylaxis (65.5% vs. 72.0%); risk difference (95% CI) 0.064 (0.0043-0.12). Only 16% of patients in whom LMWH prophylaxis was not prescribed lacked a contraindication. No significant differences in the rates of VTE (2.9% vs. 3.2%) and major bleeding (2.7% vs. 4.0%) were observed.ConclusionsE-alert v2.0 further increased the use of appropriate thromboprophylaxis in hospitalised cancer patients, although was not associated with a reduction in VTE incidence.
引用
收藏
页码:805 / 809
页数:5
相关论文
共 50 条
  • [21] Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: A single-centre experience
    Steger, GG
    Bartsch, R
    Wenzel, C
    Pluschni, U
    Hussian, D
    Sevelda, U
    Locker, GJ
    Gnant, MF
    Jakesz, R
    Zielinski, CC
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (17) : 2655 - 2661
  • [22] Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience
    Van Gestel, D.
    Van den Weyngaert, D.
    Schrijvers, D.
    Weyler, J.
    Vermorken, J. B.
    BRITISH JOURNAL OF RADIOLOGY, 2011, 84 (1000): : 367 - 374
  • [23] COVID-19 pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with haematological malignancy: A single-centre experience
    Lee, Kee Tat
    Low, Woei Chyuan
    Tan, Sui Keat
    Chiang, Su Kien
    Chew, Teng Keat
    Goh, Ai Sim
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 167 - 167
  • [24] COVID-19 pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with haematological malignancy: A single-centre experience
    Lee, Kee Tat
    Low, Woei Chyuan
    Tan, Sui Keat
    Chiang, Su Kien
    Chew, Teng Keat
    Goh, Ai Sim
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 167 - 167
  • [25] CLINICAL AND MICROBIOLOGICAL ASPECTS OF DISCONTINUATION OF QUINOLONE PROPHYLAXIS IN HAEMATOLOGICAL PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA: A SINGLE-CENTRE EXPERIENCE
    Verlinden, A.
    Vrelust, I.
    Jansens, H.
    van de Velde, A.
    Berneman, Z.
    Schroyens, W.
    Gadisseur, A.
    HAEMATOLOGICA, 2012, 97 : 173 - 173
  • [26] Clinical and microbiological aspects of discontinuation of quinolone prophylaxis in patients undergoing haematopoietic stem cell transplantation: a single-centre experience
    Verlinden, A.
    Vrelust, I.
    Jansens, H.
    de Velde, A. Van
    Berneman, Z.
    Schroyens, W.
    Gadisseur, A.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S78 - S78
  • [27] LIPOSOMAL CYTARABINE IN THE CENTRAL NERVOUS SYSTEM PROPHYLAXIS OF PATIENTS WITH NON-HODGKIN'S LYMPHOMA AND LYMPHOBLASTIC ACUTE LEUKEMIA RESULTS OF A SINGLE-CENTRE EXPERIENCE
    Santagostino, A.
    Ardizzone, F.
    Vitali, L.
    Sciacca, M.
    Zagaglia, A.
    HAEMATOLOGICA, 2008, 93 : S138 - S138
  • [28] Single-Centre Experience of Clinical Outcomes for Advanced Lung Cancer Patients in Phase I Clinical Trials
    Graham, D.
    Jordan, T.
    Tinsley, N.
    Aruketty, S.
    Vickers, A.
    Kelly, C.
    Kurup, R.
    White, A.
    Smith, A.
    Walsh, A.
    Thomson, C.
    O'Reilly, S.
    Norfolk, M.
    Chang, D.
    Blackhall, F.
    Summers, Y.
    Califano, R.
    Taylor, P.
    Thistlethwaite, F.
    Cook, N.
    Carter, L.
    Krebs, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S470 - S470
  • [29] Single-Centre Experience with Percutaneous Cryoablation of Breast Cancer in 23 Consecutive Non-surgical Patients
    Roberto Luigi Cazzato
    Christine Tunon de Lara
    Xavier Buy
    Stéphane Ferron
    Gabrielle Hurtevent
    Marion Fournier
    Marc Debled
    Jean Palussière
    CardioVascular and Interventional Radiology, 2015, 38 : 1237 - 1243
  • [30] Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition
    Lam, Jie M.
    Liu, Wing K.
    Powles, Thomas
    Tang, Yen Zhi
    Szabados, Bernadett
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (04): : 659 - 662